浙江东日公告称，公司股票于2025年11月10 - 11日连续2个交易日内日收盘价格涨幅偏离值累计达 20%，12日再次涨停，收盘价58.60元/股。鉴于连续多日涨幅较大，可能存在非理性炒作与短期大幅下 跌风险。公司主营农副产品批发交易市场运营等业务，不涉及"脑机接口"业务，截至11月11日，公司最 新市盈率166.55，远高于行业静态市盈率31.29。经自查，公司无应披露未披露重大信息，经营正常。 ...

Group 1 - The company, Chenxin Pharmaceutical (603367.SH), experienced a continuous three-day trading limit increase from July 28 to July 30, 2025 [1] - The latest static price-to-earnings (P/E) ratio for the pharmaceutical manufacturing industry is 32.03, while the company's static P/E ratio is 25.37 and rolling P/E ratio is 26.37 [1] - The company's price-to-book (P/B) ratio is 2.12, compared to the industry average of 3.16 [1] Group 2 - The trading turnover rate for the company's stock is 6.04%, indicating an increase compared to previous periods [1] - There are concerns regarding potential market overheating and irrational speculation due to the significant fluctuations in the company's stock price [1] - The rapid increase in stock price may lead to potential risks of a downturn in the short term [1]